Skip to main content

Table 1 Characteristics of the ankylosing spondylitis study population

From: Daily physical activity in ankylosing spondylitis: validity and reliability of the IPAQ and SQUASH and the relation with clinical assessments

  Total group Validity study Reliability study
Number of patients 115 63 52
Age (years) 44.6 ± 12.1 43.2 ± 12.3 46.3 ± 11.8
Gender (male) 71 (62) 40 (64) 31 (60)
Body mass index 26.4 ± 4.4 26.2 ± 4.8 26.6 ± 3.9
Duration of symptoms (years) 16 (0 to 54) 18 (2 to 54) 16 (0 to 53)
Time since diagnosis 10 (0 to 42) 11 (1 to 42) 9 (0 to 37)
HLA-B27+ 82 (76) 49 (82) 33 (69)
Anti-TNF use 78 (70) 39 (62) 39 (81)*
NSAID use 44 (40) 24 (39) 20 (42)
DMARD use 17 (15) 13 (21) 4 (8)
BASDAI (range 0 to 10) 3.7 (0.0 to 9.0) 3.8 (0.4 to 8.6) 3.5 (0.0 to 9.0)
ESR (mm/hour) 11 (2 to 60) 13 (2 to 60) 10 (2 to 39)
CRP (mg/l) 3 (2 to 46) 3 (2 to 44) 4 (2 to 46)
ASDASCRP 2.3 (0.7 to 4.4) 2.3 (0.9 to 4.2) 2.3 (0.7 to 4.4)
BASFI (range 0 to 10) 3.8 ± 2.4 3.6 ± 2.4 4.2 ± 2.4
Occiput-to-wall distance (cm) 0.0 (0.0 to 29.0) 0.0 (0.0 to 29.0) 0.0 (0.0 to 20.0)
Chest expansion (cm) 5.0 (1.0 to 14.0) 6.0 (1.0 to 10.5) 4.0 (1.0 to 14.0)**
Modified Schober test (cm) 4.0 (0.4 to 7.0) 4.0 (0.4 to 6.2) 3.9 (0.0 to 7.0)
Lateral spinal flexion (cm) 10.0 (0.0 to 27.0) 10.0 (0.0 to 25.0) 10.0 (1.8 to 27.0)
Cervical rotation (degrees) 63 (5 to 98) 70 (7 to 95) 58 (5 to 98)
ASQoL (range 0 to 18) 6 (0 to 18) 6 (0 to 17) 6 (0 to 18)
  1. Data presented as mean ± standard deviation, n (%) or median (range). ASDAS, Ankylosing Spondylitis Disease Activity Score; ASQoL, Ankylosing Spondylitis Quality of Life; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HLA-B27+, human leukocyte antigen B27-positive; NSAID, nonsteroidal anti-inflammatory drug; TNF, tumor necrosis factor. *Statistically significant difference compared to the validity study (P < 0.05). **Statistically significant difference compared to the validity study (P < 0.01).